Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results
| Autor: | Lucas, K.J., Lopez, P., Lawitz, E., Sheikh, A., Aizenberg, D., Hsia, S., Bee, G.G. Boon, Vierling, J., Frias, J., White, J., Eguchi, Y., Lazas, D., Neff, G., Yoneda, M., Augustin, S., Kim, W., Loeffler, Y., Schaefer, F., Lamle, S., Martic, M., Brass, C., Sanyal, A. |
|---|---|
| Zdroj: | In Digestive and Liver Disease February 2020 52 Supplement 1:e38-e38 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect